United Therapeutics (NASDAQ:UTHR) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
Several other analysts have also commented on the stock. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target on the stock in a research report on Monday. Oppenheimer raised their price target on shares of United Therapeutics to $180.00 and gave the company an “outperform” rating in a research report on Friday, January 5th. Wedbush restated an “outperform” rating and set a $232.00 price target (up previously from $213.00) on shares of United Therapeutics in a research report on Wednesday, December 27th. ValuEngine upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 26th. Finally, TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. United Therapeutics has a consensus rating of “Hold” and a consensus target price of $140.45.
Shares of United Therapeutics (NASDAQ UTHR) opened at $140.32 on Tuesday. The company has a market cap of $6,060.00, a price-to-earnings ratio of 12.37 and a beta of 1.41. United Therapeutics has a 52-week low of $112.01 and a 52-week high of $169.89.
In other news, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $122.00, for a total value of $70,760.00. Following the transaction, the director now directly owns 2,135 shares of the company’s stock, valued at $260,470. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 1,263 shares of the firm’s stock in a transaction dated Thursday, October 26th. The stock was sold at an average price of $120.38, for a total transaction of $152,039.94. Following the completion of the transaction, the chief executive officer now directly owns 1,403 shares in the company, valued at $168,893.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,508 shares of company stock worth $1,774,621. Company insiders own 7.80% of the company’s stock.
Large investors have recently bought and sold shares of the company. Quantbot Technologies LP lifted its stake in shares of United Therapeutics by 537.3% in the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after buying an additional 822 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of United Therapeutics in the third quarter worth about $156,000. Toronto Dominion Bank lifted its stake in shares of United Therapeutics by 244.7% in the third quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock worth $223,000 after buying an additional 1,351 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. purchased a new position in shares of United Therapeutics in the third quarter worth about $233,000. Finally, TLP Group LLC purchased a new position in shares of United Therapeutics in the second quarter worth about $246,000.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/3143666/bidaskclub-lowers-united-therapeutics-uthr-to-sell.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.